| abstract |
A method for producing a solid drug dosage form that provides improved oral availability for inhibitors of HIV protease. Solidifying a melt comprising lopinavir and ritonavir, a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50 ° C., and a pharmaceutically acceptable surfactant having an HLB value of 4 to 10. A method for producing a solid drug dosage form. Preferably, the surfactant is sorbitan monolaurate and the water soluble polymer is a copolymer of N-vinyl pyrrolidone and vinyl acetate. [Selection figure] None |